Project Grant K99CA259223
Award Date 4/1/21
Completion Date 1/15/22
Dollars Obligated $249K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02215, USA
Similar Awards
- This $330,543.28 Project Grant from the National Cancer Institute, part of the Department of Health and Human Services, was awarded under the Cancer Research Manpower federal grant program (CFDA 93.398) to Dana-Farber Cancer Institute, Inc. for the period of August 16, 2021 through March 31, 2022. The grant funds research aimed at developing a pan-cancer atlas of driver mutations in over 100,000 patients through a hypothesis-driven combined computational and experimental approach....
- The National Cancer Institute (NCI) awarded a $170,641 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, Massachusetts. The purpose of this 2-year award, which runs from August 1, 2025 to July 31, 2027, is to advance the understanding of tumor-immune spatial interactions in mismatch-repair stratified colorectal cancers. The research aims to identify immunologically distinct subsets of mismatch-repair proficient...
- The federal Project Grant award for $172,193 was provided by the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398) to the Dana-Farber Cancer Institute, Inc. (DFCI) located in Massachusetts. The goal of this 5-year project is to characterize subtype-specific gene regulatory elements in translocation renal cell carcinoma (TRCC), a rare and aggressive form of kidney cancer, by identifying differentially active transcription factors, determining their metabolic...
- The Dana-Farber Cancer Institute, Inc. (DFCI) received a $2,452,400 Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) to conduct a program titled "Convergent Epigenetic Control of Diverse Neuroendocrine Cancers". The 5-year program, which began on April 1, 2025, aims to study the epigenetic and transcriptional states required for the development of neuroendocrine cancers across four tissue types: small intestinal...
- The National Cancer Institute awarded a $148,050 Project Grant under the Cancer Research Manpower federal grant program (CFDA 93.398) to Weill Medical College of Cornell University. The grant supports research to study the role of the APOBEC3 family of cytosine deaminases in driving genomic instability and mutagenesis in lung cancer. The project aims to identify the specific APOBEC3 enzymes responsible for lung cancer mutagenesis and develop novel tools to measure APOBEC3 activity. This research...
- This $150,104 Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) supports research to understand the evolutionary trajectories of complex genomic rearrangements in cancer. The project aims to develop novel computational approaches, "AGAVE" and "ROSE", to characterize the timing and dynamics of focal amplifications and structural variants during tumor evolution. The research will map these evolutionary patterns across...
- This $238,722 federal Project Grant awarded on August 18, 2025 by the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) to the Sloan-Kettering Institute for Cancer Research supports research to investigate the role of mutagenic DNA repair during the persistence of cancer cells. The research aims to define the specific mechanisms that promote mutagenic DNA repair and drive acquired drug resistance in persister cancer cells, focusing on the role of the microhomology-mediated end...
- The U.S. National Cancer Institute awarded a $855,249 Project Grant to the Dana-Farber Cancer Institute, Inc. (DFCI) under the Cancer Treatment Research program (CFDA 93.395). The grant supports DFCI's research to develop new approaches for targeting cell cycle proteins as potential cancer treatments. The key focus is on investigating how abnormal activation of cyclin-dependent kinases (CDKs) drives uncontrolled tumor cell proliferation, and exploring strategies to overcome limitations of...
- The Department of Defense's Military Medical Research and Development program (CFDA 12.420) has awarded a $889,995.00 Project Grant to the Dana-Farber Cancer Institute, Inc. (dba Dfci), a non-profit hospital and cancer research center in Boston, MA. The grant, effective June 1, 2024 through May 31, 2027, supports research to "dissect the interplay of molecular and spatial architectures with clinical states in prostate cancer." This federal funding will enable Dana-Farber to conduct...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $136,266 to the Dana-Farber Cancer Institute, Inc. (DFCI) to support research focused on therapeutic strategies to prevent small cell lung cancer (SCLC) histological transformation. The project aims to determine the mechanisms by which inactivation of the EED gene promotes the transformation from SCLC to lung adenocarcinoma (LUAD), as well as how RB1 inactivation mediates...